Letermovir 480 MG [Prevymis]

Phase 2Recruiting

2 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cytomegalovirus Infections

Conditions

Cytomegalovirus Infections, Transplant-Related Disorder

Trial Timeline

Apr 4, 2024 → Aug 15, 2026

NCT ID

NCT06066957

About Letermovir 480 MG [Prevymis]

Letermovir 480 MG [Prevymis] is a phase 2 stage product being developed by Merck for Cytomegalovirus Infections. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06066957. Target conditions include Cytomegalovirus Infections, Transplant-Related Disorder.

What happened to similar drugs?

8 of 20 similar drugs in Cytomegalovirus Infections were approved

Approved (8) Terminated (1) Active (11)

✅LetermovirMerckApproved

✅Single arm (ganciclovir and valganciclovir)RocheApproved

✅Ganciclovir + valganciclovir [Valcyte]RocheApproved

✅ValganciclovirRocheApproved

✅valganciclovir [Valcyte]RocheApproved

✅Valganciclovir + CMV hyperimmune globulin + ValganciclovirCSLApproved

✅CytogamKamadaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07101055	Phase 1	Recruiting	Sep 1, 2025	Dec 1, 2027	End-Stage Kidney Disease (ESKD)
NCT06066957	Phase 2	Recruiting	Apr 4, 2024	Aug 15, 2026	Cytomegalovirus Infections

Competing Products

20 competing products in Cytomegalovirus Infections

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
ASP0113 + Placebo	Astellas Pharma	Phase 2	35
ASP0113 + Placebo	Astellas Pharma	Phase 3	40
Letermovir oral granules + Letermovir tablet + Letermovir intravenous	Merck	Phase 2	35
Letermovir 240 mg Oral Tablet	Merck	Phase 2	42
Letermovir tablet + Letermovir IV	Merck	Phase 3	40
Letermovir	Merck	Phase 1	36
Letermovir	Merck	Approved	43
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID	Merck	Phase 1	29
Ganciclovir	Merck	Pre-clinical	26
Letermovir + Placebo	Merck	Phase 3	40
Letermovir	Merck	Phase 2	35